Full history for every metric is available with a Kvantra account
Dali Pharmaceuticalco.,Ltd (603963.SS)
Key financial summary
Financials in CNY| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 401 | 294 | 214 | 171 | 132 | 87 | 60 |
| Operating profit | CNY m | -17 | -25 | |||||
| Net profit | CNY m | 11 | 14 | 3 | -42 | -18 | -20 | -24 |
| EPS reported | CNY | -0.09 | -0.11 | |||||
| Operating cashflow per share | CNY | -0.12 | -0.12 | |||||
| Capex per share | CNY | 0.03 | 0.03 | |||||
| FCF per share | CNY | -0.15 | -0.15 | |||||
| Free cash flow | CNY m | -34 | -2 | |||||
| Net debt | CNY m | -198 | -197 | |||||
| Book value equity | CNY m | 381 | 361 | |||||
| Book value per share | CNY | 1.71 | 1.64 | |||||
| Number of shares | m | 222.57 | 219.7 | |||||
| DPS (TTM paid) | CNY | 0.01 | 0.00 |
Financial summary
Financials in CNY| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 6.94 | 0.72 | |||||
| P/S LTM | x | 30.30 | 4.29 | |||||
| P/FCF LTM | x | -78.45 | -130.66 | |||||
| EV/EBITDA LTM | x | 7,690.48 | -4.73 | |||||
| EV/Sales LTM | x | 30.41 | 1.03 | |||||
| Earnings Yield LTM | % | -0.76% | -7.63% | |||||
| FCF Yield | % | -1.27% | -0.77% | |||||
| Quality | ||||||||
| ROE | % | -5.26% | -5.12% | |||||
| ROIC | % | -4.21% | -4.21% | |||||
| Operating margin | % | -19.52% | -19.52% | |||||
| Gross margin | % | 41.59% | 41.59% | |||||
| FCF/Sales | % | -38.62% | -38.62% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -34.06% | -42.58% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.06% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | -8.17% | -4.27% | |||||
| FCF/Debt | x | -1.42 | -0.18 | |||||
| Net Debt/EBITDA | x | 27.44 | 27.44 | |||||
| EBIT/Net interest | x | -9.88 | -9.88 | |||||
| Net debt/market cap | % | -7.49% | -76.06% | |||||
| Net debt/Equity | x | -0.52 | -0.55 | |||||
| Gross debt/equity | x | 0.06 | 0.03 | |||||
Company overview
Dali Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm engaged in the research, development, manufacturing, and distribution of medicinal products. The company specializes in injectable medications, offering a diverse portfolio of both traditional Chinese and Western formulations. This includes 20 distinct drug varieties, with a total of 44 approved specifications. Key examples from their product line are Xingnaojing, Shenmai, Astragalus, Leucocin A, and Citicoline injections. Dali Pharmaceutical also maintains a substantial intellectual property collection, holding 31 patents comprised of 11 invention patents, 16 utility models, and 3 design patents. Established in 1996, the company operates from its headquarters located in Dali, China.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Dali Pharmaceuticalco.,Ltd (603963.SS)
Dali Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm engaged in the research, development, manufacturing, and distribution of medicinal products. The company specializes in injectable medications, offering a diverse portfolio of both traditional Chinese and Western formulations. This includes 20 distinct drug varieties, with a total of 44 approved specifications. Key examples from their product line are Xingnaojing, Shenmai, Astragalus, Leucocin A, and Citicoline injections. Dali Pharmaceutical also maintains a substantial intellectual property collection, holding 31 patents comprised of 11 invention patents, 16 utility models, and 3 design patents. Established in 1996, the company operates from its headquarters located in Dali, China.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free